Limits...
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.

Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H - Br. J. Cancer (2010)

Bottom Line: Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in enhanced anticancer activity.The most common adverse events were rash and diarrhoea.The combination of sirolimus and erlotinib for RCC failed to demonstrate an advantage over available single-agent therapy in the second-line setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Department of Medicine, University of Colorado Denver School of Medicine, Mail Stop 8117, 12801 East 17th Avenue Room 8117, Aurora, CO 80045, USA. Thomas.Flaig@UCDenver.edu

ABSTRACT

Background: The mammalian target of rapamycin (mTOR) is an important therapeutic target in the treatment of renal cell carcinoma (RCC). Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in enhanced anticancer activity.

Methods: All patients had metastatic RCC with progression after treatment with sunitinib and/or sorafenib. Treatment consisted of erlotinib 150 mg orally once a day starting on day 1 and sirolimus 6 mg orally on day 8 followed by 2 mg daily, adjusted according to blood levels.

Results: A total of 25 patients were enrolled between July 2006 and March 2008. The median progression-free survival (PFS) was 12 weeks (95% CI 5.9-18.1) and median overall survival (OS) 40 weeks (95% CI 0-85.7). No confirmed complete or partial responses were observed, but stable disease >6 months was noted in 21.8% (95% CI 4.9-38.6) of patients. The most common adverse events were rash and diarrhoea. There was no correlation between erlotinib, OSI-420 (days 8 and 15) or sirolimus (days 15 and 29) blood levels and PFS or OS.

Conclusions: The combination of sirolimus and erlotinib for RCC failed to demonstrate an advantage over available single-agent therapy in the second-line setting.

Show MeSH

Related in: MedlinePlus

(A) Evidence of tumour response. Soft tissue pelvic mass measuring 55 mm at baseline (left panel) vs 30 mm at cycle 11 (right panel); (B) a second pelvic mass in the same patient, 50 mm at baseline and 34 mm at cycle 11. Other target lesions were stable and this subject did not meet RECIST criteria for a partial response.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2966634&req=5

fig3: (A) Evidence of tumour response. Soft tissue pelvic mass measuring 55 mm at baseline (left panel) vs 30 mm at cycle 11 (right panel); (B) a second pelvic mass in the same patient, 50 mm at baseline and 34 mm at cycle 11. Other target lesions were stable and this subject did not meet RECIST criteria for a partial response.

Mentions: Several patients had notable reduction in the size of some tumours, although none of these reductions met the RECIST criteria for a partial response. Figure 3 shows an example of a significant reduction in the size of two pelvic tumours, although tumours in the patient's abdomen later grew during the course of his therapy, leading to progressive disease after completing 48 weeks with SD.


Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.

Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H - Br. J. Cancer (2010)

(A) Evidence of tumour response. Soft tissue pelvic mass measuring 55 mm at baseline (left panel) vs 30 mm at cycle 11 (right panel); (B) a second pelvic mass in the same patient, 50 mm at baseline and 34 mm at cycle 11. Other target lesions were stable and this subject did not meet RECIST criteria for a partial response.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2966634&req=5

fig3: (A) Evidence of tumour response. Soft tissue pelvic mass measuring 55 mm at baseline (left panel) vs 30 mm at cycle 11 (right panel); (B) a second pelvic mass in the same patient, 50 mm at baseline and 34 mm at cycle 11. Other target lesions were stable and this subject did not meet RECIST criteria for a partial response.
Mentions: Several patients had notable reduction in the size of some tumours, although none of these reductions met the RECIST criteria for a partial response. Figure 3 shows an example of a significant reduction in the size of two pelvic tumours, although tumours in the patient's abdomen later grew during the course of his therapy, leading to progressive disease after completing 48 weeks with SD.

Bottom Line: Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in enhanced anticancer activity.The most common adverse events were rash and diarrhoea.The combination of sirolimus and erlotinib for RCC failed to demonstrate an advantage over available single-agent therapy in the second-line setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Oncology, Department of Medicine, University of Colorado Denver School of Medicine, Mail Stop 8117, 12801 East 17th Avenue Room 8117, Aurora, CO 80045, USA. Thomas.Flaig@UCDenver.edu

ABSTRACT

Background: The mammalian target of rapamycin (mTOR) is an important therapeutic target in the treatment of renal cell carcinoma (RCC). Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in enhanced anticancer activity.

Methods: All patients had metastatic RCC with progression after treatment with sunitinib and/or sorafenib. Treatment consisted of erlotinib 150 mg orally once a day starting on day 1 and sirolimus 6 mg orally on day 8 followed by 2 mg daily, adjusted according to blood levels.

Results: A total of 25 patients were enrolled between July 2006 and March 2008. The median progression-free survival (PFS) was 12 weeks (95% CI 5.9-18.1) and median overall survival (OS) 40 weeks (95% CI 0-85.7). No confirmed complete or partial responses were observed, but stable disease >6 months was noted in 21.8% (95% CI 4.9-38.6) of patients. The most common adverse events were rash and diarrhoea. There was no correlation between erlotinib, OSI-420 (days 8 and 15) or sirolimus (days 15 and 29) blood levels and PFS or OS.

Conclusions: The combination of sirolimus and erlotinib for RCC failed to demonstrate an advantage over available single-agent therapy in the second-line setting.

Show MeSH
Related in: MedlinePlus